iCare announces updated MAIA TrueColor Microperimetry System
The updated device is designed to meet market diagnostic needs, including within geographic atrophy research
The MAIA's structure-function correlation has been improved as a result of the 60-degree TrueColor field of view. Image courtesy of iCare.
iCare, an ophthalmic device company with headquarters in Finland and Italy, shared an update on the release of the newest version of the iCare MAIA microperimeter. The company said the iCare MAIA microperimeter is in its final stages of preparation. The commercial launch of the new version is scheduled for the first quarter of 2025.
The updated iCare MAIA has a renewed hardware platform with fully automated operations and 15’ multi-touch display. The auto-alignment capability in the device is also useful, as it keeps the device aligned with the eye under exam. The structure-function correlation has been improved as well as a result of the 60-degree TrueColor field of view.
“iCare MAIA retains all the key elements that made it the gold standard in microperimetry technology,” Daniele Mantovano, iCare’s business line director diagnostic, said in the new release. “The introduction of the 60° TrueColor imaging capabilities brings the new MAIA to the next level of structure-function correlation in microperimetry. We strongly believe in microperimetry and its usefulness in the research ophthalmic segment, and we have been intensely working on this project since the discontinuation of the previous MAIA model.”
With these new improvements to the iCare MAIA, its onboard grid editor now allows ophthalmologists to create customised test patterns, providing higher flexibility for the execution of custom protocols for patient-specific testing. It can also import data from the previous model and use it as a reference for follow-up examination.
In a press release, iCare described the capabilities of the new MAIA system, calling it “a significant step in our growth and innovation strategy.” According to the news release from iCare, the updated MAIA system pinpoints market diagnostic needs, particularly within the ophthalmic research segment focusing on development of therapies for geographic atrophy.
